NCT06246110: A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 70 | US | EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin | Eikon Therapeutics | NSCLC | 12/26 | 12/27 | | |
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 247 | Europe | Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT | Institut BergoniƩ, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics | Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer | 09/24 | 03/26 | | |